Avanos Medical (AVNS) Expected to Announce Earnings on Tuesday

Avanos Medical (NYSE:AVNS) is expected to be announcing its Q4 2025 results before the market opens on Tuesday, February 24th. Analysts expect Avanos Medical to post earnings of $0.24 per share and revenue of $174.70 million for the quarter. Interested persons can check the company’s upcoming Q4 2025 earning summary page for the latest details on the call scheduled for Tuesday, February 24, 2026 at 9:00 AM ET.

Avanos Medical Price Performance

NYSE AVNS opened at $15.47 on Friday. The company has a debt-to-equity ratio of 0.12, a quick ratio of 1.36 and a current ratio of 2.38. The stock has a market cap of $718.02 million, a price-to-earnings ratio of -1.52 and a beta of 1.09. The business has a 50 day simple moving average of $12.79 and a 200 day simple moving average of $11.98. Avanos Medical has a 52-week low of $9.30 and a 52-week high of $16.63.

Institutional Trading of Avanos Medical

A number of institutional investors have recently made changes to their positions in AVNS. Corient Private Wealth LLC bought a new position in Avanos Medical in the fourth quarter valued at $234,000. Vident Advisory LLC acquired a new position in shares of Avanos Medical during the 4th quarter worth about $585,000. State of Tennessee Department of Treasury grew its holdings in shares of Avanos Medical by 50.0% in the 4th quarter. State of Tennessee Department of Treasury now owns 41,405 shares of the company’s stock valued at $465,000 after acquiring an additional 13,799 shares in the last quarter. EP Wealth Advisors LLC acquired a new stake in shares of Avanos Medical in the fourth quarter valued at about $201,000. Finally, NewEdge Advisors LLC raised its holdings in Avanos Medical by 36,740.6% during the fourth quarter. NewEdge Advisors LLC now owns 48,998 shares of the company’s stock worth $550,000 after acquiring an additional 48,865 shares in the last quarter. Institutional investors own 95.17% of the company’s stock.

Analyst Ratings Changes

AVNS has been the subject of several research reports. Wall Street Zen raised shares of Avanos Medical from a “buy” rating to a “strong-buy” rating in a research report on Saturday, November 8th. Zacks Research raised shares of Avanos Medical from a “strong sell” rating to a “hold” rating in a research report on Monday, January 26th. Finally, Weiss Ratings reiterated a “sell (d-)” rating on shares of Avanos Medical in a report on Monday, December 22nd. One equities research analyst has rated the stock with a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, the stock has an average rating of “Reduce”.

Avanos Medical Company Profile

Avanos Medical is a global medical technology company that develops and markets a broad portfolio of medical devices intended to improve patient outcomes in hospital, outpatient and post-acute care settings. The company’s products focus on three core therapy areas—pain management, enteral feeding and respiratory care—designed to help clinicians manage post-operative pain, deliver nutrition support and assist breathing for patients across a variety of acute and chronic conditions.

In its pain management segment, Avanos offers both non-opioid drug delivery systems and cryoanalgesia devices, including ambulatory infusion pumps and cooled radiofrequency ablation platforms.